title: Linezolid resistance in a clinical isolate of Staphylococcus aureus.
abstract: The new oxazolidinone antimicrobial, linezolid, has been approved for the treatment of infections caused by various gram-positive bacteria, including meticillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Although instances of linezolid resistance in VRE have been reported, resistance has not been encountered among clinical isolates of S aureus. We have characterised an MRSA isolate resistant to linezolid that was recovered from a patient treated with this agent for dialysis-associated peritonitis.
authors.forename: S
authors.initials: S
authors.lastname: Tsiodras
authors.forename: H S
authors.initials: HS
authors.lastname: Gold
authors.forename: G
authors.initials: G
authors.lastname: Sakoulas
authors.forename: G M
authors.initials: GM
authors.lastname: Eliopoulos
authors.forename: C
authors.initials: C
authors.lastname: Wennersten
authors.forename: L
authors.initials: L
authors.lastname: Venkataraman
authors.forename: R C
authors.initials: RC
authors.lastname: Moellering
authors.forename: M J
authors.initials: MJ
authors.lastname: Ferraro
mesh_terms: D000081:Acetamides / Q000494:pharmacology* / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006801:Humans; D000069349:Linezolid; D008297:Male; D016106:Methicillin Resistance; D023303:Oxazolidinones / Q000494:pharmacology* / Q000627:therapeutic use; D010538:Peritonitis / Q000188:drug therapy / Q000382:microbiology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects*
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D011500:Protein Synthesis Inhibitors; D000069349:Linezolid